HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy

Lexicon

PMDA-WEST:
医薬品医療機器総合機構関西支部

The Column

3 Reasons Why KOL Management Is No Longer Enough

Archives

MHLW Warns of Hyperbilirubinemia in Patients on Sovriad(Nov.27)
Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research(Nov.27)
Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official(Nov.27)
ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President(Nov.27)
Janssen Files NDA for Anticancer Agent Ibrutinib in Japan(Nov.27)

Most Read

1.
Don’t Use Long-...
2.
CareNet Teams U...
3.
Top Two Japan U...
4.
PhRMA Chair Pro...
4.
3 Straight Year...

News Calendar